Daniel Louis Yokell, Pharm.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fluorine Radioisotopes | 5 | 2021 | 424 | 0.660 |
Why?
|
| Radiopharmaceuticals | 9 | 2024 | 2734 | 0.510 |
Why?
|
| Carbolines | 4 | 2016 | 296 | 0.410 |
Why?
|
| Misonidazole | 1 | 2012 | 33 | 0.410 |
Why?
|
| Positron-Emission Tomography | 11 | 2024 | 6670 | 0.390 |
Why?
|
| Microfluidics | 2 | 2014 | 674 | 0.290 |
Why?
|
| Isoquinolines | 2 | 2019 | 354 | 0.270 |
Why?
|
| Receptor, Muscarinic M4 | 1 | 2024 | 16 | 0.230 |
Why?
|
| tau Proteins | 4 | 2019 | 2143 | 0.210 |
Why?
|
| Oxygen | 2 | 2015 | 4273 | 0.190 |
Why?
|
| Radiochemistry | 2 | 2017 | 50 | 0.170 |
Why?
|
| Fragile X Syndrome | 1 | 2021 | 116 | 0.170 |
Why?
|
| Demyelinating Diseases | 1 | 2022 | 358 | 0.170 |
Why?
|
| Macaca mulatta | 1 | 2024 | 2362 | 0.140 |
Why?
|
| Radiometry | 1 | 2022 | 817 | 0.140 |
Why?
|
| Gallium Radioisotopes | 2 | 2013 | 195 | 0.130 |
Why?
|
| Onium Compounds | 1 | 2015 | 27 | 0.120 |
Why?
|
| Neurofibrillary Tangles | 1 | 2017 | 459 | 0.120 |
Why?
|
| Silicates | 1 | 2013 | 49 | 0.110 |
Why?
|
| Glass | 1 | 2013 | 116 | 0.110 |
Why?
|
| Aminopyridines | 1 | 2017 | 580 | 0.100 |
Why?
|
| Octreotide | 1 | 2013 | 155 | 0.100 |
Why?
|
| Receptors, Somatostatin | 1 | 2013 | 138 | 0.100 |
Why?
|
| Iodine | 1 | 2015 | 286 | 0.100 |
Why?
|
| Isotope Labeling | 1 | 2013 | 395 | 0.100 |
Why?
|
| Boron Compounds | 1 | 2013 | 196 | 0.090 |
Why?
|
| Quinolines | 1 | 2017 | 768 | 0.090 |
Why?
|
| Intestinal Neoplasms | 1 | 2013 | 316 | 0.090 |
Why?
|
| Nitriles | 1 | 2015 | 984 | 0.080 |
Why?
|
| Molecular Imaging | 1 | 2016 | 827 | 0.080 |
Why?
|
| Neuroendocrine Tumors | 1 | 2013 | 658 | 0.070 |
Why?
|
| Alzheimer Disease | 2 | 2019 | 8747 | 0.060 |
Why?
|
| Tissue Distribution | 2 | 2022 | 2299 | 0.060 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2013 | 1536 | 0.060 |
Why?
|
| Cyclic S-Oxides | 1 | 2024 | 25 | 0.060 |
Why?
|
| Cerebral Cortex | 2 | 2021 | 5831 | 0.060 |
Why?
|
| Azabicyclo Compounds | 1 | 2024 | 68 | 0.060 |
Why?
|
| Automation | 2 | 2017 | 588 | 0.050 |
Why?
|
| Brain | 4 | 2024 | 27454 | 0.050 |
Why?
|
| Pyridines | 1 | 2015 | 2889 | 0.050 |
Why?
|
| Carbon Radioisotopes | 1 | 2024 | 567 | 0.050 |
Why?
|
| Allosteric Regulation | 1 | 2024 | 423 | 0.050 |
Why?
|
| Peptides | 1 | 2013 | 4353 | 0.050 |
Why?
|
| Fragile X Mental Retardation Protein | 1 | 2021 | 115 | 0.050 |
Why?
|
| Cell Proliferation | 1 | 2013 | 10478 | 0.040 |
Why?
|
| Halogenation | 1 | 2017 | 46 | 0.040 |
Why?
|
| Membrane Potentials | 1 | 2020 | 1090 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 20765 | 0.030 |
Why?
|
| Aging | 1 | 2015 | 8764 | 0.030 |
Why?
|
| Kinetics | 1 | 2024 | 6333 | 0.030 |
Why?
|
| Metabolic Clearance Rate | 1 | 2016 | 363 | 0.030 |
Why?
|
| Quality Control | 1 | 2017 | 833 | 0.030 |
Why?
|
| Hydrolysis | 1 | 2015 | 646 | 0.030 |
Why?
|
| Chemical Fractionation | 1 | 2013 | 60 | 0.030 |
Why?
|
| Electrons | 1 | 2015 | 264 | 0.030 |
Why?
|
| Solubility | 1 | 2013 | 1085 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2016 | 1967 | 0.020 |
Why?
|
| Aniline Compounds | 1 | 2015 | 1094 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2014 | 1539 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2013 | 1998 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2020 | 5313 | 0.020 |
Why?
|
| Gene Expression | 1 | 2021 | 7598 | 0.020 |
Why?
|
| Thiazoles | 1 | 2015 | 1542 | 0.020 |
Why?
|
| Temperature | 1 | 2015 | 2235 | 0.020 |
Why?
|
| Temporal Lobe | 1 | 2015 | 1728 | 0.020 |
Why?
|
| Male | 6 | 2024 | 364902 | 0.020 |
Why?
|
| Myocardium | 1 | 2020 | 4788 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2019 | 3579 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2013 | 3632 | 0.020 |
Why?
|
| Humans | 10 | 2022 | 768393 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2013 | 6132 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2013 | 3617 | 0.020 |
Why?
|
| Animals | 3 | 2024 | 169337 | 0.010 |
Why?
|
| Middle Aged | 4 | 2021 | 223491 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2021 | 11918 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2016 | 6277 | 0.010 |
Why?
|
| Aged, 80 and over | 2 | 2019 | 59686 | 0.010 |
Why?
|
| Amyloid beta-Peptides | 1 | 2015 | 3910 | 0.010 |
Why?
|
| Female | 4 | 2024 | 397089 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2013 | 10776 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 14737 | 0.010 |
Why?
|
| Aged | 3 | 2019 | 171562 | 0.010 |
Why?
|
| Models, Biological | 1 | 2016 | 9493 | 0.010 |
Why?
|
| Adult | 3 | 2021 | 223640 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 20224 | 0.010 |
Why?
|
| Rats | 1 | 2013 | 23835 | 0.010 |
Why?
|
| Time Factors | 1 | 2015 | 40272 | 0.010 |
Why?
|
| Prognosis | 1 | 2013 | 30022 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2013 | 65379 | 0.000 |
Why?
|
| Mice | 1 | 2013 | 82017 | 0.000 |
Why?
|